



A target product profile (TPP) for antibiotics to treat severe enteric infections in low- and middle-income countries (LMICs)

AGENDA

10:00 - 12:00

- Welcome by GNA NOW and CARB-X
- Presentations from LMIC on the clinical reality in their countries
- Panel discussion:
 - What is the current situation?
 - What are the characteristics of the ideal drug that the LMIC clinics need?
 - What would a phase 3 study look like?
- Wrap-up: conclusions and next steps to finalize and publish the TPP

PANELLISTS

- Valeria Gigante (WHO)
- Seamus O'Brien (GARDP)
- Dorothy Yeboah-Manu (NMIMR, University of Ghana)
- David Paterson (Saw Swee Hock School of Public Health, Singapore)
- Samuel Mungai Kariuki (DNDi, Kenya)
- Joseph (Herb) Harwell (Clinton Health Access Initiative)

Chair: Erin Duffy, CARB-X



SCAN QR CODE FOR
ONLINE PROGRAM



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853979: 'GNA NOW: Gram-Negative Antibacterials NOW'. The JU receives support from the European Union's Horizon 2020 research and innovation programme and is part of the AMR Accelerator.

